AZNAstraZenecaFinished
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 50 (final count)
- Started
- Nov 7, 2022
- Main results expected
- Nov 20, 2024
- Fully finished
- Sep 16, 2025
- Results posted
- Sep 25, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review
Measured over: Approx. 4 to 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05498155 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC